• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DaVita celebrates kidney care community achievements in year one of largest-ever value-based care program

    10/22/24 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email

    Nephrologists drive transformative outcomes through government's coordinated care program serving high-need patients

    DENVER, Oct. 22, 2024 /PRNewswire/ -- DaVita today announced performance year one clinical outcomes achieved in partnership with nearly 1,300 nephrologists across the U.S. through value-based care arrangements designed to enhance the lives of Medicare patients with kidney disease. As the broader health care community continues to explore value-based care arrangements to improve health outcomes in the U.S., DaVita commends the efforts from likeminded specialty care providers leading the movement.

    These efforts have helped lead the kidney care community through scaled participation and investment in these programs, which are part of the Comprehensive Kidney Care Contracting (CKCC) option within the government's voluntary Kidney Care Choices (KCC) model — a value-based care demonstration that began on Jan. 1, 2022, as the largest government model for kidney care.

    "This program relies on the understanding that kidney care in the U.S. has been fragmented and that a system that better coordinates these care silos is better for our patients. When our patients do better, they can live a better life and cost the system less money. Those savings can be wrapped around to provide even better care — and the cycle continues," said Dr. Gregory Spin, clinical leader for the Northern California Kidney Care Choices group and founding partner of Summit Nephrology. "We have worked hard to share best practices across our program, and DaVita has amplified that process by bringing learnings from other participants."

    Together with participating nephrologists, DaVita launched 11 value-based care arrangements in 2022 and has since doubled that footprint to 22 Kidney Contracting Entities (KCEs). An evaluation now available for the first performance year (PY1) demonstrates that these value-based care arrangements result in better patient outcomes, which, over time, should lead to decreasing cost expenditures. This includes engaging patients in their care earlier and supporting access to kidney transplants for patients managing their kidney health.

    Physicians and providers in the CKCC program improved outcomes for patients through collective quality metrics, with a 16% industry increase in optimal start rates for kidney patients transitioning to dialysis. Reducing unplanned starts leads to more optimal outcomes for patients, with care teams better coordinating their kidney and non-kidney care needs as well as improving interventions to help keep them healthy and out of the hospital, while also reducing high health care costs.

    "Our focus at the launch of the program was to provide robust support for our nephrology partners, and we're encouraged by the current momentum. Though scaled transformation takes time, we continue to trend positively into the third year of the program," said Dr. Amy Schuerman-Gen, chief medical officer for DaVita Integrated Kidney Care (DaVita IKC). "Our vision for care innovation is taking shape, with CKCC laying a vital foundation for lasting change. The model's emphasis on care coordination and patient engagement has already led to encouraging health outcomes, and we're optimistic about the program's potential for continued success."

    DaVita and its nephrologist partners have already seen significant progress over the course of the CKCC program and expect the impact on outcomes and cost savings will continue to improve. Achievements include:

    • Embedding care team members in 68% of nephrology practices, providing care to shared patients directly at the site of care.
    • Overseeing approximately 31,000 patients across dialysis centers of multiple providers, remotely, and in nephrologist offices.
    • Enabling 2.4x more DaVita patients to have a planned start on home treatment through patient education, care management and transition support.
    • Screening 67% of patients for depression remission with a baseline PHQ-9 across 11 KCEs, supporting holistic care of both physical and mental health.
    • Increasing patient activation by 13%, indicating higher patient engagement across patient populations — inclusive of people with chronic kidney disease (CKD) and people with end-stage kidney disease (ESKD) who do not treat at DaVita.

    Care coordination is fueled in part by DaVita's tech-enabled platform, with more than half of participants either leveraging DaVita's co-designed EHR with Epic or allowing DaVita access to another platform. This foundation helps to meet patients earlier with crucial identification and education to help slow progression to kidney failure and avoid dialysis. From PY1 to current year-to-date, DaVita has increased CKD education by 39% via Kidney Smart®, an award-winning, interactive community and virtual education program, for patients aligned with CKCC practices.

    From coast to coast, participation in CKCC has allowed for a broad evaluation of the positive impact value-based care at scale can have for kidney patients.

    "As we continue in the CKCC demonstration, I look forward to working collaboratively with our DaVita IKC partners and others to tackle difficult challenges we face in patient-centered care," said Dr. Alec Otteman of Associated Nephrology Consultants in St. Paul, MN. "We continue to work through how to best support patients to prevent hospitalizations and readmissions, and our DaVita IKC partners can create wrap-around support for medication reconciliation and transition of care post-hospitalization."

    For more information about DaVita IKC's programs and results, visit DaVita.com/IKC 

    About DaVita Inc.

    DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of June 30, 2024, DaVita served approximately 265,100 patients at 3,124 outpatient dialysis centers, of which 2,672 centers were located in the United States and 452 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

    Forward-Looking Statements 

    Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties. These forward-looking statements are based on management's current expectations. Various important factors could cause actual results to differ materially from these forward-looking statements, including the risks identified in our U.S. Securities and Exchange Commission filings. DaVita disclaims any obligation to update any forward-looking statement contained in this press release, except as may be otherwise required by law.

    The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.

    Media Contact:

    DaVita Newsroom

    [email protected] 

    DaVita Logo (PRNewsfoto/DaVita)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-celebrates-kidney-care-community-achievements-in-year-one-of-largest-ever-value-based-care-program-302282733.html

    SOURCE DaVita

    Get the next $DVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What recent announcement has DaVita made regarding their kidney care initiatives for Medicare patients?

      DaVita has announced significant clinical outcomes achieved through the CKCC program which launched in 2022, aimed at improving kidney care for Medicare patients.

    • What specific improvement in patient outcomes has been observed in the CKCC program?

      The CKCC program has seen participants report a 16% increase in optimal starting rates for kidney patients transitioning to dialysis, leading to improved outcomes.

    • How many Kidney Contracting Entities (KCEs) has DaVita launched as part of their value-based care arrangements?

      DaVita and participating nephrologists have doubled their footprint from 11 to 22 Kidney Contracting Entities (KCEs) within the CKCC program since its inception.

    • What change in patient engagement has been reported in the CKCC program?

      Patient engagement and activation have increased by 13% among CKD and ESKD patients, illustrating improved engagement in their health care.

    • How is technology being leveraged within the CKCC program to improve patient education and care coordination?

      The CKCC program utilizes a tech-enabled platform to enhance care coordination, which has led to a 39% increase in CKD education through DaVita's Kidney Smart program.

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    10/29/2021$113.00 → $111.00Sector Perform
    RBC Capital
    More analyst ratings

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

    Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.DENVER, March 18, 2026 /PRNewswire/ -- DaVita today highlighted continued progress in value-based kidney care, underscoring how sustained investment in coordinated care models is translating into improved outcomes for people living with kidney disease. That progress is evident across both industry partnerships with major insurers and scaled programs sponsored by the Center for Medicare & Medicaid Innovation (CMMI).For more than two dec

    3/18/26 3:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

    AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysisAlebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therapeutics, a newly launched company backed by leading global kidney care providers and life sciences strategic and venture capital investorsThe collaboration includes potential milestone payments of up to low triple-digit millions of U.S. dollars and tiered royalties in the low double-digit percentage range based on net sales of AP306 in the licensed territoryAlebund holds a substantial non-dilutive equit

    3/17/26 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

    Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal CarePartnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate Advancing Phase 2b clinical development of AP306 as a monotherapy for hyperphosphatemia in patients with chronic kidney disease on dialysis REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc ("R1"), a clinical-stage biopharmaceutical company focused on the development of first-in-class thera

    3/17/26 7:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arway Pamela M was granted 332 shares, increasing direct ownership by 1% to 26,695 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:27 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Desoer Barbara J was granted 332 shares (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:18 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Chief Operating Officer, DKC Maughan David Paul was granted 5,308 shares and covered exercise/tax liability with 13,107 shares, decreasing direct ownership by 6% to 114,467 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    3/17/26 4:10:04 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    SEC Filings

    View All

    SEC Form 10-K filed by DaVita Inc.

    10-K - DAVITA INC. (0000927066) (Filer)

    2/11/26 4:06:39 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DAVITA INC. (0000927066) (Filer)

    2/2/26 4:07:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - DAVITA INC. (0000927066) (Filer)

    11/25/25 5:01:10 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on DaVita with a new price target

    Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

    3/6/24 8:09:27 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita upgraded by UBS with a new price target

    UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

    8/7/23 7:20:56 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously

    11/1/22 9:18:39 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    View All

    DaVita Appoints Jessica Hergenreter as Chief People Officer

    DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

    10/17/24 1:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

    DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

    9/13/24 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints New Chief Information Officer

    Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

    5/13/24 9:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Financials

    Live finance-specific insights

    View All

    DaVita Inc. 4th Quarter 2025 Results

    DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion

    2/2/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call

    DENVER, Jan. 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Monday, February 2, 2026 at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Monday, February 2, 2026Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen

    1/21/26 10:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 3rd Quarter 2025 Results

    DENVER, Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended September 30, 2025. "Our third quarter performance was in line with our expectations and keeps us on track to achieve our full-year guidance," said Javier Rodriguez, CEO of DaVita. "Our consistent focus on providing outstanding care is the key to these results, enabling us to continuously invest in improving the lives of our patients and supporting our dedicated teammates and physician partners." Financial and operating highlights for the quarter ended September 30, 2025: Consolidated revenues were $3.420 billion.Operating income was $506 million and adjusted operating

    10/29/25 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/13/24 5:02:42 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/9/22 3:43:35 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

    SC 13D/A - DAVITA INC. (0000927066) (Subject)

    8/4/21 4:02:59 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care